Search

everythinglearnresearchcommunity

for

Search:↓

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

User reports 3-month progress using daily 1mg finasteride, 0.5ml minoxidil (2x daily), 0.5ml dutasteride, and derma rolling 0.5mm 1-2 times per week. They see increased density on crown and top of head, slight progress in corners and temples, and recently added cosmerna.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.

The post is about a discount on a 6-month supply of Minoxidil at Costco. The conversation includes users discussing their experiences with purchasing and using Minoxidil, with some mentioning regional price differences and preferences for foam or liquid forms.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is happy with their hair transplant results after 6 months, using minoxidil and PRP sessions, but is unsure about not addressing the temples. Others reassure them that the hairline looks natural and age-appropriate, though some suggest considering finasteride or dutasteride for maintenance.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.